Provectus Biopharmaceuticals, Inc. Stock
Equities
PVCT
US74373P1084
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1911 USD | -3.73% | -1.90% | +99.06% |
Sales 2022 | 0.99 1.35 | Sales 2023 | 0.56 0.76 | Capitalization | 40.27M 55M |
---|---|---|---|---|---|
Net income 2022 | -3M -4.1M | Net income 2023 | -3M -4.1M | EV / Sales 2022 | 48,121,944 x |
Net Debt 2022 | 2.16M 2.95M | Net Debt 2023 | 2.95M 4.03M | EV / Sales 2023 | 77,502,175 x |
P/E ratio 2022 |
-12.8
x | P/E ratio 2023 |
-13
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.58% |
1 day | -3.73% | ||
1 week | -1.90% | ||
Current month | +4.48% | ||
1 month | +0.53% | ||
3 months | +69.26% | ||
6 months | +150.13% | ||
Current year | +99.06% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 71 | 18-04-26 |
Eric A. Wachter
FOU | Founder | 61 | 01-12-31 |
Heather Raines
DFI | Director of Finance/CFO | 58 | 17-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric A. Wachter
FOU | Founder | 61 | 01-12-31 |
John W. Lacey
BRD | Director/Board Member | 76 | 18-04-26 |
President | 55 | 17-04-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.1911 | -3.73% | 21 290 |
24-04-26 | 0.1985 | +1.07% | 39,686 |
24-04-25 | 0.1964 | +1.24% | 251,000 |
24-04-24 | 0.194 | -0.41% | 67,734 |
24-04-23 | 0.1948 | 0.00% | 138,051 |
Delayed Quote OTC Markets, April 29, 2024 at 12:35 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+99.06% | 83.28M | |
-2.64% | 103B | |
+1.65% | 95.28B | |
+1.46% | 22.15B | |
-15.55% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.74% | 16.05B | |
+5.33% | 13.68B | |
+34.15% | 12.17B |
- Stock Market
- Equities
- PVCT Stock